The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study
Open accessAbstract
PURPOSE: Patients with severe eosinophilic asthma often experience recurrent asthma exacerbations despite intensive inhaled corticosteroid therapy. In 2 previous double-blind studies (MENSA [NCT01691521] and SIRIUS [NCT01691508]), treatment with intravenous or subcutaneous mepolizumab was associated with significantly reduced annualized exacerbation rates and oral corticosteroid (OCS) requirements compared with placebo. The purpose of this study was to assess the long-term safety and efficacy of subcutaneous mepolizumab treatment in patients with severe eosinophilic asthma. METHODS: COSMOS was a 52-week, open-label extension study in patients who received mepolizumab or placebo in MENSA or SIRIUS. Patients received subcutaneous mepolizumab regardless of prior treatment allocation and continued to receive appropriate standard-of-care asthma therapy throughout. The primary objective was to assess the long-term safety of mepolizumab; end points included adverse events (AEs) and serious AEs (SAEs). Efficacy assessments included the annualized exacerbation rate and durability of response (defined as the exacerbation rate and OCS dose reduction when combined with MENSA and SIRIUS data, respectively). FINDINGS: In total, 558 (86%; previous mepolizumab: 358; previous placebo: 200) and 94 (14%; previous mepolizumab: 58, previous placebo: 36) patients experienced on-treatment AEs and SAEs, respectively. No fatal AEs were reported. Totals of 13 (2%) and 29 (4%) patients experienced systemic and local site reactions, respectively. There were no reports of mepolizumab-related anaphylaxis. Mepolizumab treatment was shown to exert a durable response, with patients who previously received mepolizumab in MENSA or SIRIUS maintaining reductions in exacerbation rate and OCS dosing throughout COSMOS. Patients who previously received placebo in MENSA or SIRIUS demonstrated improvements in these end points following treatment with mepolizumab in COSMOS. IMPLICATIONS: These data demonstrate a favorable safety profile of mepolizumab and indicate a durable and stable effect over time, supporting long-term treatment in patients with severe eosinophilic asthma. ClinicalTrials.gov identifier: NCT01842607.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Chung, K. F., Wenzel, S. E., Brozek, J. L., Bush, A., Castro, M., Sterk, P. J., Adcock, I. M., Bateman, E. D., Bel, E. H., Bleecker, E. R., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00202013 · Cited by 3,926
Self-citationMepolizumab Treatment in Patients with Severe Eosinophilic Asthma
Ortega, H. G., Liu, M. C., Pavord, I. D., Brusselle, G. G., FitzGerald, J. M., Chetta, A., Humbert, M., Katz, L. E., Keene, O. N., Yancey, S. W., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403290 · Cited by 2,322
Self-citationSampson, H. A., Muñoz-Furlong, A., Campbell, R. L., Adkinson, N. F., Bock, S. A., Branum, A., Brown, S. G. A., Camargo, C. A., Cydulka, R., Galli, S. J., et al. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.12.1303 · Cited by 2,313
Pavord, I. D., Korn, S., Howarth, P., Bleecker, E. R., Buhl, R., Keene, O. N., Ortega, H., & Chanez, P. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60988-x · Cited by 2,221
Self-citationMechanisms involved in the side effects of glucocorticoids
SCHACKE, H. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00297-8 · Cited by 1,847
Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma
Bel, E. H., Wenzel, S. E., Thompson, P. J., Prazma, C. M., Keene, O. N., Yancey, S. W., Ortega, H. G., & Pavord, I. D. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403291 · Cited by 1,661
Self-citationSevere asthma: from characteristics to phenotypes to endotypes
Wenzel, S. (2012) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2011.03929.x · Cited by 336
Acute and chronic systemic corticosteroid–related complications in patients with severe asthma
Lefebvre, P., Duh, M. S., Lafeuille, M.-H., Gozalo, L., Desai, U., Robitaille, M.-N., Albers, F., Yancey, S., Ortega, H., Forshag, M., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.07.046 · Cited by 214
Self-citationFixed airflow obstruction due to asthma or chronic obstructive pulmonary disease: 5-year follow-up
Contoli, M., Baraldo, S., Marku, B., Casolari, P., Marwick, J. A., Turato, G., Romagnoli, M., Caramori, G., Saetta, M. P., Fabbri, L. M., et al. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.01.003 · Cited by 152
EAACI position statement on asthma exacerbations and severe asthma
Custovic, A., Johnston, S. L., Pavord, I., Gaga, M., Fabbri, L., Bel, E. H., Le Souëf, P., Lötvall, J., Demoly, P., Akdis, C. A., et al. (2013) · Allergy · doi:10.1111/all.12275 · Cited by 127
Cited by
Targeting cytokines to treat asthma and chronic obstructive pulmonary disease
Barnes, P. J. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0006-6 · Cited by 418
Eosinophil responses during COVID-19 infections and coronavirus vaccination
Lindsley, A. W., Schwartz, J. T., & Rothenberg, M. E. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.04.021 · Cited by 354
Gans, M. D., & Gavrilova, T. (2020) · Paediatric Respiratory Reviews · doi:10.1016/j.prrv.2019.08.002 · Cited by 306
Khatri, S., Moore, W., Gibson, P. G., Leigh, R., Bourdin, A., Maspero, J., Barros, M., Buhl, R., Howarth, P., Albers, F. C., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.09.033 · Cited by 304
Self-citationWinthrop, K. L., Mariette, X., Silva, J. T., Benamu, E., Calabrese, L. H., Dumusc, A., Smolen, J. S., Aguado, J. M., & Fernández-Ruiz, M. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.02.002 · Cited by 259
Metadata
- Authors
- Lugogo, N., Domingo, C., Chanez, P., Leigh, R., Gilson, M. J., Price, R. G., Yancey, S. W., & Ortega, H. G.
- Venue
- Clinical Therapeutics
- Publisher
- Elsevier BV
- Published
- 2016-09
- Volume
- 38
- Issue
- 9
- Pages
- 2058-2070.e1
- ISSN
- 0149-2918 (ISSN-L)
- OpenAlex
- W2515998798
- Cited by
- 283
- References
- 15
- FWCI
- 21.22
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study. https://app.cochat.ai/papers/10.1016/j.clinthera.2016.07.010
- The paper
- Lugogo, N., Domingo, C., Chanez, P., Leigh, R., Gilson, M. J., Price, R. G., Yancey, S. W., & Ortega, H. G. (2016). Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study. Clinical Therapeutics. https://doi.org/10.1016/j.clinthera.2016.07.010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.